Literature DB >> 10617543

Incidence of venous thromboembolism in users of combined oral contraceptives. Methods for identifying cases and estimating person time at risk must be detailed.

H Jick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10617543      PMCID: PMC1117330     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  7 in total

1.  DoH seems to have underestimated incidence of venous thromboembolism in users of combined oral contraceptives.

Authors:  R A Lawrenson; A Whalley; E Simpson; R D Farmer
Journal:  BMJ       Date:  1999-08-07

Review 2.  Principles of epidemiological research on adverse and beneficial drug effects.

Authors:  H Jick; L A García Rodríguez; S Pérez-Gutthann
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

3.  Venous thromboembolism among new users of different oral contraceptives.

Authors:  R M Herings; J Urquhart; H G Leufkens
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

4.  Population-based study of risk of venous thromboembolism associated with various oral contraceptives.

Authors:  R D Farmer; R A Lawrenson; C R Thompson; J G Kennedy; I R Hambleton
Journal:  Lancet       Date:  1997-01-11       Impact factor: 79.321

5.  Third-generation oral contraceptives and venous thrombosis.

Authors:  N R Poulter; C L Chang; M Marmot; T M Farley; O Meirik
Journal:  Lancet       Date:  1997-03-08       Impact factor: 79.321

6.  Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.

Authors:  K W Bloemenkamp; F R Rosendaal; F M Helmerhorst; H R Büller; J P Vandenbroucke
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

7.  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

Authors:  H Jick; S S Jick; V Gurewich; M W Myers; C Vasilakis
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.